ReviewAdvances in therapy2026
Advances in Clinical Cardiology 2025: A Summary of Key Clinical Trials.
Review in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOver the course of 2025, numerous key clinical trials in the field of cardiology were published or presented at major international conferences. This review seeks to collate and summarise these trials and reflect on their clinical context. With the rapid advancements in the management of cardiovascular diseases, it is critical to evaluate the emerging evidence that may influence clinical practice and impact the development of future guidelines.
methodsThe authors evaluated all clinical trials presented at major cardiology conferences during 2025, with a focus on those likely to influence or change current clinical practice. We reviewed clinical trials presented at all major international cardiology conferences, including the American College of Cardiology (ACC), European Association for Percutaneous Cardiovascular Interventions (EuroPCR), European Society of Cardiology (ESC), Transcatheter Cardiovascular Therapeutics (TCT), American Heart Association (AHA) and the European Heart Rhythm Association (EHRA) among others. Trials considered to have the highest impact and broad relevance across the field of clinical cardiology, with a strong likelihood to change or impact clinical practice, were included.
resultsOver 80 key cardiology clinical trials were identified across the spectrum of clinical cardiology in 2025. Important updates in percutaneous coronary intervention were reviewed, including advances in antiplatelet strategies challenging the traditional one-year paradigm of dual antiplatelet therapy (TARGET FIRST, MASTER DAPT), alongside key developments in percutaneous coronary intervention (PCI) and drug-coated balloon (DCB) technologies (SELUTION DeNovo, AGENT IDE). Structural heart disease trials included important updates in transcatheter valve intervention and related therapies (DAPA-TAVI, FAITAVI, BHF PROTECT-TAVI), as well as key data in left atrial appendage closure (CLOSURE-AF). Major advances were also reported in heart failure and cardiomyopathy (SUMMIT, MAPLE-HCM, DIGIT-HF), together with important preventive cardiology outcomes data (VESALIUS-CV).
conclusionThis review offers a concise synthesis of the key clinical cardiology trials published or presented over the past year, with relevance for both clinicians and cardiovascular researchers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.